Gene · 2693
GHSR: growth hormone secretagogue receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GHSR: growth hormone secretagogue receptor. Genes, record 2693. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2693
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q92847 | Growth hormone secretagogue receptor type 1 | 366 | 10 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 48357 | Q92847 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 727 | Q92847 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1706 | Q92847 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1706 | Q92847 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 727 | Q92847 | Espacenet |
| US 11548942 B2 | 2023-01-10 | 5 | Q92847 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 36532 | Q92847 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 6794 | Q92847 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 139503 | Q92847 | Espacenet |
| US 10781253 B2 | 2020-09-22 | 5 | Q92847 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs13
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ANAMORELIN | CHEMBL2110579 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| ANAMORELIN HYDROCHLORIDE | CHEMBL2103794 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| CAPROMORELIN | CHEMBL113313 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| IBUTAMOREN | CHEMBL13817 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| IBUTAMOREN MESYLATE | CHEMBL2105872 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| MACIMORELIN | CHEMBL278623 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| MACIMORELIN ACETATE | CHEMBL2364617 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| PF-5190457 | CHEMBL3287218 | Ghrelin receptor inverse agonist | INVERSE AGONIST | ChEMBL |
| RELAMORELIN | CHEMBL4297525 | Ghrelin receptor agonist | AGONIST | ChEMBL |
| TABIMORELIN | CHEMBL281764 | Ghrelin receptor agonist | AGONIST | ChEMBL |
1 to 10 of 13
See all 13 drugsTrials31
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05364684 | IBUTAMOREN | PHASE2 | 2026-01-06 | ClinicalTrials.gov |
| NCT04844970 | ANAMORELIN HYDROCHLORIDE | PHASE2 | 2025-11-17 | ClinicalTrials.gov |
| NCT03743064 | ANAMORELIN | PHASE3 | 2024-06-26 | ClinicalTrials.gov |
| NCT03743051 | ANAMORELIN | PHASE3 | 2024-06-26 | ClinicalTrials.gov |
| NCT03637816 | ANAMORELIN HYDROCHLORIDE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT03426345 | RELAMORELIN | PHASE3 | 2021-08-06 | ClinicalTrials.gov |
| NCT03420781 | RELAMORELIN | PHASE3 | 2021-12-22 | ClinicalTrials.gov |
| NCT03285308 | RELAMORELIN | PHASE3 | 2021-07-29 | ClinicalTrials.gov |
| NCT02357420 | RELAMORELIN | PHASE2 | 2019-07-24 | ClinicalTrials.gov |
| NCT02137642 | RELAMORELIN | PHASE1 | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsNIH grants1,393
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GHSR papers | Newest fiscal year |
|---|---|---|---|
| ZIADA000635 | Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN) | 14 | 2025 |
| I01BX002807 | The Role of Ghrelin and the GHSR-1a receptor in Sarcopenic Obesity | 8 | 2025 |
| P30DK017047 | Diabetes Research Center | 8 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA056036 | Translational Research in Cancer | 5 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 5 | 2025 |
| P30DK035816 | Nutrition Obesity Research Center | 5 | 2025 |
| P30ES005022 | Rutgers Center for Environmental Exposure and Disease (CEED) | 5 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 4 | 2025 |
| P30DK026687 | New York Obesity Research Center | 4 | 2025 |
1 to 10 of 1,393Source NIH's project files
See all 1,393 nih grantsPapers3,015
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management. | JCO Oncol Pract | 2026 | 42826357 | PubTator, text mining | PubMed |
| Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review. | Metabol Open | 2026 | 42750798 | PubTator, text mining | PubMed |
| Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation. | Cancers (Basel) | 2026 | 42738261 | PubTator, text mining | PubMed |
| Experiences and Behavior During a Virtual Reality Buffet Simulation: A Secondary Analysis of a Ghrelin-Related Pharmacology Randomized Controlled Trial in People with Alcohol Use Disorder. | J Med Ext Real | 2026 | 42724156 | PubTator, text mining | PubMed |
| Exploring Inhibitory Impacts of Anamorelin on Colorectal Cancer Proliferation via Regulation of Transketolase. | Curr Med Chem | 2026 | 42693844 | PubTator, text mining | PubMed |
| Periodontitis and Mechanical Forces Modulate Ghrelin Receptor in Periodontal Tissues. | APMIS | 2026 | 42692551 | PubTator, text mining | PubMed |
| Meta-inflammation through the lens of macrophage programming and nutrient-sensing ghrelin signaling. | Immunometabolism (Cobham) | 2026 | 42565088 | PubTator, text mining | PubMed |
| Activation of GHSRs Facilitates the Excitability of Dentate Gyrus Granule Cells and Short-Term Spatial Memory via Multiple Ionic and Signaling Mechanisms. | Adv Biol (Weinh) | 2026 | 42552604 | PubTator, text mining | PubMed |
| Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study. | Int J Clin Pharmacol Ther | 2026 | 42544527 | PubTator, text mining | PubMed |
| A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA). | J Cachexia Sarcopenia Muscle | 2026 | 42411631 | PubTator, text mining | PubMed |
1 to 10 of 3,015
See all 3,015 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2693
GET https://conductscience.org/api/genes/v1/2693/patents?page=2